November 8, 2007 - Point-of-care blood analysis systems company Abaxis Inc. said today the FDA granted waived status for its comprehensive metabolic panel, basic metabolic panel and electrolyte panel, allowing lab-accurate comprehensive health screenings in nearly any environment.
Four analytes for chloride (Cl-), potassium (K), sodium (Na), and total carbon dioxide (tCO2), were granted waived status by the FDA when used in conjunction with the Piccolo and Piccolo Xpress point-of-care analyzers.
“With these important CLIA waivers, the healthcare community has the new and unique capability to conduct immediate comprehensive health assessments at the point-of-care and begin patient triage with a high degree of accuracy and certainty - all without the burden of conforming to complex laboratory requirements,” said Dr. Steven Kazmierczak, professor of pathology at Oregon Health and Science University.
The Abaxis CLIA waived menu of health panels now includes: a comprehensive metabolic panel, basic metabolic panel, electrolyte panel, kidney check, lipid panel, lipid panel plus, liver panel plus, general chemistry 6, and general chemistry 13.
For more information: www.abaxis.com